Showing 3601-3610 of 4063 results for "".
- Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the UShttps://modernod.com/news/alcon-announces-broad-retail-availability-of-pataday-once-daily-relief-extra-strength-in-the-u-s/2478886/Alcon announced that Pataday Once Daily Relief Extra Strength is now available in-store and online at U.S. retailers following its 2020 approval by the FDA for sale over the counter (OTC). As Alcon’s third Rx-to-OTC switch in the past 12 months, Pataday Once Daily Relief Extra Strength (o
- Ophthalmic Fundraising Activity Soars in Face of Pandemichttps://modernod.com/news/ophthalmic-fundraising-activity-soars-in-face-of-pandemic/2478884/The ophthalmic market continues to expand and attract funding from investors. There were more deals in 2020 than the two previous years, and transactions totaled $8.6 billion, according to a new Market Scope report. Retina is the largest ophthalmic market sector, driven by a booming pharma
- Eyevance’s Natacyn Now Available for Next-Day Deliveryhttps://modernod.com/news/eyevances-natacyn-now-available-next-day/2478883/Eyevance Pharmaceuticals announced that its anti-fungal ophthalmic medication, Natacyn (natamycin ophthalmic suspension 5%), is now available for next-day delivery. Natacyn, which Eyevance acquired from Novartis in 2019, is indicated for the treatment of fungal blepharitis, conjunctivitis,
- New World Medical’s Next-Generation KDB GLIDE Now Commercially Availablehttps://modernod.com/news/new-world-medicals-next-generation-kdb-glide-now-commercially-available/2478880/New World Medical announced the launch of the KDB GLIDE device for advanced excisional goniotomy treatment of glaucoma. The KDB GLIDE, which was registered with the FDA in October 2020, is now commercially available to ophthalmic surgeons across the US looking for refined, precise performance dur
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-positive-interim-data-in-visual-and-erg-clinical-outcomes-in-the-electrolight-pilot-study-in-dry-amd-patients/2478872/LumiThera announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 we
- Kala Pharmaceuticals Announces Eysuvis Now Covered by Express Scriptshttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-express-scripts/2478871/Kala Pharmaceuticals announced that pharmacy benefit manager Express Scripts has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred, Basic and High Performance Formularies, effective February 5, 2021. Eysuvis is the first and only prescription therapy appr
- Euclid Systems Announces Expansion of Leadership Teamhttps://modernod.com/news/euclid-systems-announces-expansion-of-leadership-team/2478845/Euclid Systems has announced expansion of its leadership team. Joseph Boorady, OD, FAAO, appointed to the position of president and chief executive officer in January 2020, brings over 25 years of experience in the ophthalmic industry as an eye care professional, educational leader, entrepreneur
- GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primateshttps://modernod.com/news/gensight-biologics-announces-the-publication-in-communications-biology-of-the-proof-of-concept-for-gs030-drug-product-in-none28091human-primates/2478834/GenSight Biologics announced that the journal Communications Biology has published results from the study of GS030-Drug Product (GS030-DP) in non-human primates (NHP). The paper,* published in the January issue under the title “Optogenetic therapy: high spatiotemporal resolution and
- Jazz to Buy Cannabinoid Drugmaker GW Pharma in $7.2-Billion Dealhttps://modernod.com/news/jazz-to-buy-cannabinoid-drugmaker-gw-pharma-vva-7-2-billion-deal/2478832/Jazz Pharmaceuticals entered into a definitive agreement to acquire GW Pharmaceuticals for $220 per share, or a total consideration of $7.2 billion, adding the latter’s cannabinoid product platform, including Epidiolex (cannabidiol), to its neuroscience pipeline, the companies announced Wed
- Inflammasome Therapeutics Says Study Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-says-study-provides-human-data-confirming-potential-of-companys-proprietary-compounds-for-prevention-of-dry-amd/2478824/Inflammasome Therapeutics reported that data analyses published in the current issue of Proceedings of the National Academy of Sciences (PNAS) confirms that the company’s proprietary compounds hold significant promise in the prevention and treatment of dry age-related macular degeneration